Background: BAL30376 combines the siderophore monobactam BAL19764 (Syn/PTX 2416) with the bridged monobactam BAL29880 to inhibit AmpC enzymes and with clavulanate to inhibit extended-spectrum b-lactamases (ESBLs). We tested BAL30376 and its components versus isolates and laboratory strains of Enterobacteriaceae and non-fermenters.
Introduction
The spread of extended-spectrum b-lactamases (ESBLs) and AmpC enzymes is increasing the prevalence of cephalosporin resistance among Enterobacteriaceae and driving carbapenem use. 1 Carbapenem resistance is slowly emerging too, owing to: (i) the selection of Klebsiella pneumoniae and Enterobacter strains with combinations of ESBL or AmpC and impermeability; 2 (ii) the dissemination of plasmids encoding VIM, IPM and NDM metallo-carbapenemases among Enterobacteriaceae and nonfermenters; 3, 4 (iii) the spread of K. pneumoniae clones with KPC carbapenemases; 5 (iv) the spread of OXA-48 carbapenemases in K. pneumoniae; 6 and (v) the accumulation of multiple OXA carbapenemase types in Acinetobacter baumannii clones, some of which have disseminated widely. 7 It is difficult to envisage any b-lactam stable to all these diverse enzymes, or any inhibitor inactivating them all. One answer nevertheless might be to protect a b-lactam with multiple inhibitors. BAL30376 attempts this by combining the dihydroxypyridone monobactam BAL19764 (Syn2146, PTX2416; Figure 1 ) with clavulanate to inhibit ESBLs and the bridged monobactam BAL29880 to inhibit AmpC enzymes. As a siderophore, BAL19764 might be anticipated to enter Gram-negative bacteria via non-porin routes involved in iron uptake, potentially also overcoming impermeability and overwhelming efflux. As a monobactam, it also should be stable to metallo-carbapenemases. We investigated how well these objectives were achieved, using mutants, transconjugants and isolates with known resistance mechanisms.
Materials and methods

Test strains
The test strains were reference mutants, transconjugants and transformants, or recent submissions to the Antibiotic Resistance Monitoring and Reference Laboratory. They comprised: (i) Enterobacteriaceae mutants varying in expression of chromosomal b-lactamasesthose with AmpC derepression were spontaneous mutants whilst those with basal expression were generated by exposure to nitrosoguanidine; 8 (ii) Escherichia coli K-12 J53/62 or DH5a and Pseudomonas aeruginosa PU21 transconjugants and transformants with acquired b-lactamases; 8, 9 (iii) clinical Enterobacteriaceae with or without ESBLs, high-level AmpC or carbapenemases collected either as reference submissions or from a recent survey; 10 (iv) multiresistant clinical P. aeruginosa and Burkholderia cepacia complex isolates from cystic fibrosis (CF) patients, collected as reference laboratory submissions; 9 and (v) multiresistant A. baumannii isolates, again collected as submissions to the reference laboratory. Several major national clones, e.g. A. baumannii OXA-23 clone 1 and SE clone 11, 12 and E. coli ST131 UK strain A, 13 were strongly represented in the collections, as were members of the 'Liverpool' CF-adapted strain of P. aeruginosa (see the Results section). 14 
MIC determinations
MICs were determined by CLSI agar dilution on Mueller-Hinton medium (Oxoid/Thermofisher, Basingstoke, UK). For BAL19764 and its combinations, this medium was supplemented with 16 mg/L 2,2 ′ -bipyridyl to chelate Fe 3+ and induce TonB-mediated uptake. 15 To formulate BAL30376, BAL19764 was combined with BAL29880 at 4 mg/L and clavulanate at 2 mg/L; alternatively a 5:3:1 ratio was used. Comparators were aztreonam, imipenem, meropenem and piperacillin/ tazobactam (4 mg/L).
Results
b-Lactamase expression mutants
Most AmpC-inducible organisms were as susceptible to BAL19764 as their AmpC-deficient (DEF) mutants; moreover, most MICs for these organisms were ≤1 mg/L (Table 1) , although there were exceptions, for example Citrobacter freundii C4 and C4-DEF, with BAL19764 MICs of 2-4 mg/L. AmpC-derepressed organisms were less susceptible, with MICs ranging from 1 to 4 mg/L for derepressed Serratia marcescens up to 64 -128 mg/L for derepressed E. cloacae. These patterns suggest that, like aztreonam and oxyimino-cephalosporins, BAL19764 is labile to AmpC b-lactamases but is a weak inducer of their synthesis below MIC. The carbapenems kept near-equal activity regardless of AmpC expression, reflecting their known stability to these enzymes.
As expected, clavulanate had little effect on the MICs of BAL19764 for AmpC-derepressed strains, but BAL29880 4 mg/L reduced them to ≤2 mg/L and usually to ≤0.5 mg/L, with BAL30376 retaining this level of activity and proving slightly more active when tested with fixed inhibitor concentrations than as a 5:3:1 fixed ratio.
BAL29880 did not potentiate BAL19764 against the AmpCinducible or -basal organisms, confirming that the synergy against derepressed organisms was contingent on inhibition of AmpC.
E. coli transconjugants and transformants
ESBLs raised the MICs of both BAL19764 and aztreonam, though the effect was small for many organisms with CTX-M enzymes other than CTX-M-15. CTX-M-15, SHV-4 and -5, and TEM-3 and -10 enzymes had a greater effect, raising the MICs of both unprotected monobactams to ≥32 mg/L. Clavulanate, but not BAL29880, reduced these values to ≤0.5 mg/L, with this activity maintained by BAL30376.
The MIC of BAL30376 exceeded 32 mg/L for a transconjugant with KPC-3 enzyme but was only 4 mg/L for one with NMC-A blactamase, another Class A carbapenemase, compared with 64 mg/L for unprotected BAL19764. E. coli DH5a transformants with IMP-1, NDM-1 (alone) and OXA-48 carbapenemases remained susceptible to both BAL19764 and BAL30376 at ≤0.06 mg/L, whereas a transformant with both NDM-1 enzyme and a CMY-type AmpC enzyme was resistant to BAL19764 (MIC, 16 mg/L) but susceptible to BAL30376 (MIC, 0.06 mg/L). It should be added that the transformation recipient E. coli DH5a is intrinsically very susceptible to b-lactams, implying a high degree of permeability, potentially militating against efficient b-lactamase function. This factor probably underlies the low carbapenem MICs for the transformants with OXA-48 and IMP-1 enzymes.
Clinical isolates of Enterobacteriaceae
Cephalosporin-and aztreonam-susceptible wild-types
MICs for 107 control isolates of E. coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia spp. and Morganella morganii are detailed in Table 2 . These organisms were selected as lacking phenotypic resistance to aztreonam and oxyimino-cephalosporins K. oxytoca, high-level K1 enzyme (n ¼25 
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Activity of BAL30376
and as lacking mechanisms known to affect these agents. MICs of aztreonam were consistently ≤2 mg/L, with modes of ≤0.008 -0.12 mg/L, according to the species. All were susceptible to carbapenems, though some were resistant to piperacillin/tazobactam, probably contingent on hyperproduction of TEM-1 or similar penicillinases or on production of inhibitor-resistant penicillinases such as OXA-1. MICs of BAL19764 were widely scattered, with a suggestion of bimodal character for E. coli and Klebsiella spp., where there were distribution peaks at 0.015 and 0.125-0.25 mg/L. Most MICs for unprotected BAL19764 were lower than those of aztreonam, but a few values were higher, with 7/107 isolates non-susceptible at 1 mg/L, including one Enterobacter sp. with an MIC of 8 mg/L. Five of these seven isolates were also resistant to BAL30376, 1 mg/L, with little reduction in MIC values compared with the unprotected compound.
AmpC-hyperproducing isolates
MICs of BAL19764 for AmpC-derepressed clinical isolates (Table 2) were widely scattered, but mostly were substantially raised compared with those for the control isolates. 131/181 were resistant to unprotected BAL19764 at MIC 1 mg/L, with modal MICs of 32 mg/L for E. coli, 64 mg/L for Enterobacter spp. and 32 mg/L for Citrobacter spp. Addition of BAL29880 reduced these modal MICs to 0.5 mg/L for Enterobacter spp., Citrobacter spp. Serratia spp. and M. morganii, though only to 4-8 mg/L for E. coli, with similar activity seen for BAL30376. Unsurprisingly, clavulanate alone had little effect on the MICs of BAL19764. Sixty-nine percent of the isolates were susceptible to BAL30376 at 1 mg/L and 85% at 4 mg/L.
Imipenem and meropenem retained good activity, with MICs≤ 2 mg/L, versus all the derepressed isolates except in the case of imipenem against M. morganii, a species with inherently poor susceptibility to this agent.
ESBL-producing Enterobacteriaceae and K. oxytoca with K1 enzyme
MICs of unprotected BAL19764 for ESBL-positive E. coli were bimodally distributed, with peaks at 4 and .128 mg/L, whereas distributions for ESBL-producing Klebsiella, Enterobacter, Citrobacter and Serratia spp. were unimodal, with peaks .64 mg/L. The bimodal MIC distribution of BAL19764 for E. coli was recapitulated by aztreonam, with peaks at 4 and 128 mg/L. Addition of BAL29880 had little effect, whereas clavulanate reduced the modal MIC values to 0.25 -0.5 mg/L for all species groups, with similar activity retained by BAL30376, as tested with fixed inhibitor concentrations. A few isolates were less susceptible and, based on results with fixed inhibitor concentrations, 7/102 (7%) E. coli, 25/111 (23%) Klebsiella and 8/41 (20%) Enterobacter, Citrobacter and Serratia spp. were resistant to BAL30376 at 1 mg/L and 2/102 (2%), 8/111 (7%), and 5/41 (12%), respectively, at 4 mg/L. Imipenem and meropenem retained activity at 2 mg/L against all the organisms except for one K. pneumoniae.
Forty-three ESBL-positive E. coli belonged to strain A, a widespread UK lineage with CTX-M-15 enzyme, also recorded from Italy and Austria. 13 MICs of BAL30376 for members of this strain ranged from 0.06 to 8 mg/L.
K. oxytoca isolates hyperproducing K1 enzyme were consistently resistant to unprotected BAL19764, with MICs≥ 16 mg/L and mostly ≥128 mg/L (Table 2) ; they were resistant also to piperacillin/tazobactam and aztreonam, as is typical for the phenotype, but not to carbapenems. BAL30376, as tested with fixed inhibitor concentrations, had a modal MIC of 2 -4 mg/L for these K. oxytoca, with values .4 mg/L for 8/25 isolates.
Carbapenem-resistant Enterobacteriaceae
Four groups of carbapenem-resistant Enterobacteriaceae isolates were tested (Table 2 ). These variously had: (i) combinations of impermeability and ESBL or AmpC enzymes; (ii) IMP, VIM or NDM metallo-b-lactamases (MBLs); (iii) OXA-48 carbapenemase; or (iv) KPC carbapenemases. Those with impermeability together with a b-lactamase were resistant to ertapenem based on previous testing but were variable in resistance to imipenem and meropenem, as is typical of the phenotype. 2 MICs of unprotected BAL19764 were widely scattered but exceeded .64 mg/L for 86% of these organisms; MICs of BAL30376 were lower, but 35% of values remained ≥16 mg/L and 59% remained .1 mg/L (as tested with the fixed inhibitor concentrations). For comparison: 98% of the isolates were resistant to aztreonam, 1 mg/L; 78% of the isolates were resistant to piperacillin/tazobactam, 16 mg/L; 41% of the isolates were resistant to meropenem, 2 mg/L; and 15% of the isolates were resistant to imipenem, 2 mg/L.
MICs of unprotected BAL19764 for the 35 isolates with MBLs ranged from 0.03 to .128 mg/L, with 21/35 values .128 mg/L. Most of the highest values were for isolates with NDM-1 enzyme, which is commonly determined by plasmids that also encode one or more AmpC enzyme; the host strains often also have CTX-M ESBLs (M. Doumith, S. Mahrajan, S. Mushtaq, N. Woodford and 
Activity versus P. aeruginosa mutants
Derepressed AmpC in P. aeruginosa mutants was associated with MICs of 32-64 mg/L for unprotected BAL19764 and aztreonam compared with 2-4 mg/L for the corresponding AmpC-inducible and -deficient organisms (Table 3) . BAL29880 reduced the MICs of BAL19764 for the derepressed organisms to the baseline of 2 -4 mg/L, with similar results recorded for BAL30376. Loss of porin OprD did not affect the MICs of BAL19764 or BAL30376, but raised those of carbapenems.
P. aeruginosa PU21 transconjugants
OXA-2, -10 and -14 enzymes raised the MICs of unprotected BAL19764 to 16 mg/L for P. aeruginosa transconjugants compared with 2 mg/L for the plasmid-free recipient (Table 3) . Similar behaviour was seen for aztreonam, though raised aztreonam MICs were more clearly associated with generally agreed known OXA ESBL enzymes, namely OXA-11, -14, -15 and -16. MICs of BAL30376 for transconjugants with OXA ESBLs were only minimally reduced compared with those of BAL19764; however, a BAL19764 MIC of .128 mg/L for a PER-1 + transconjugant was reduced to 4 mg/L by clavulanate or BAL30376. Surprisingly, RP4 plasmid, encoding TEM-2 enzyme, raised the MIC of BAL19764 from 2 to 16 mg/L, with this rise reversed by clavulanate or BAL30376, confirming the role of the b-lactamase; TEM-2 had no such effect on the MICs of aztreonam or carbapenems.
Clinical isolates of non-fermenters
P. aeruginosa with efflux-determined resistance
We determined MICs for 87 P. aeruginosa isolates that varied in resistance to existing b-lactams, including aztreonam, but lacked derepressed AmpC or acquired b-lactamases. Representatives were previously shown to vary in MexAB-OprM-mediated efflux, which was inferred to be the major modulator of resistance in the collection. 16 MICs of BAL19764, like those of piperacillin/tazobactam and meropenem, rose in tandem with aztreonam MICs, whereas those of imipenem, which evades MexAB-OprM, were less related (Table 4) . 17 Since b-lactamases were not involved in this resistance, the MICs of BAL30376 closely resembled those of unprotected BAL19764, with both around 4-fold below those of aztreonam.
CF isolates of P. aeruginosa and B. cepacia
The CF isolates were highly multiresistant, reflecting submission bias to a reference laboratory: among P. aeruginosa isolates 74% were resistant to piperacillin/tazobactam, 16 mg/L; 88% to imipenem, 4 mg/L; 72% to meropenem, 4 mg/L; and 70% to aztreonam, 16 mg/L ( Table 5) .
MICs of unprotected BAL19764 exceeded 16 mg/L for 38/50 (76%) of the P. aeruginosa isolates; they were typically reduced by 4-to 8-fold by BAL29880, not clavulanate, implying a contribution by derepressed AmpC. Despite these reductions, the MICs of BAL30376 remained .16 mg/L for 58% of isolates with the fixed inhibitor concentrations and .46% with the fixed ratio.
Among the B. cepacia isolates, 64% were resistant to aztreonam, 16 mg/L; 88% to imipenem, 4 mg/L; 52% to piperacillin/ tazobactam, 16 mg/L and 30% to meropenem, 4 mg/L. Unprotected BAL19764 behaved differently from any comparator, with a bimodal MIC distribution. Half the isolates (25/50) required MICs.128 mg/L, whereas the MICs for the other 25 were scattered from 0.015 to 4 mg/L with a mode of 1 mg/L. Inhibitors had no appreciable effect on these distributions, which were recapitulated for BAL30376. Isolates in the lower part of the distribution were inhibited by aztreonam at concentrations between 2 and 64 mg/L, whereas those with BAL19764 MICs.128 mg/L were resistant to aztreonam at 128 mg/L.
MBL-producing P. aeruginosa
MICs for 19 MBL-producing P. aeruginosa isolates are shown in Table 5 
Activity against carbapenem-resistant A. baumannii
Two hundred A. baumannii isolates were tested; 143 belonged to OXA-23 clone 1 and 27 to the SE clone, which are prevalent around London. 11, 12 The former has OXA-23 and the latter commonly has ISAba1-upregulated OXA-51-like carbapenemase. 18 The remaining 30 were diverse but included 4 with IMP MBLs, 14 with OXA-23 enzyme, 2 with OXA-40, 9 with OXA-58 and 1 with up-regulated OXA-51 enzyme. Over 90% were resistant to aztreonam (16 mg/L), carbapenems (4 mg/L) and piperacillin/ tazobactam (16 mg/L) ( Table 6 ).
The MIC distributions of unprotected BAL19764 and BAL30376 for OXA-23 clone 1 and the SE clone were both centred at 2 mg/L, with over 85% of values between 1 and 4 mg/L. Nevertheless, and irrespective of the presence of the b-lactamase inhibitors, a few OXA-23 clone 1 isolates required substantially higher MICs, ranging above 128 mg/L. MICs of BAL19764 for the 30 A. baumannii isolates not belonging to the two major clones were more widely scattered, with 13 values .128 mg/L, indicating a higher prevalence of resistance than among members of the two major clones. The activity of BAL30376 was little better than that of BAL19764. Susceptibility to the monobactams was not a reflection of carbapenemase type, with OXA-23, -51-like and -58 carbapenemases all represented among the isolates with high and low MICs.
Discussion
These data illustrate the potential and limits of combining an MBL-stable monobactam with multiple b-lactamase inhibitors; BAL19764 had broad anti-Gram-negative activity, inhibiting 100/107 wild-type, cephalosporin-and aztreonam-susceptible Enterobacteriaceae at ≤1 mg/L, and wild-type P. aeruginosa at 2-4 mg/L. MICs for a few wild-type Enterobacteriaceae nevertheless ranged up to 8 mg/L, compared with a maximum of 2 mg/L for aztreonam. This pattern of occasional resistance among otherwise susceptible groups or strains (e.g. even within E. coli strain A 13 and A. baumannii OXA-23 clone 1) was repeatedly seen with BAL19764 and BAL30376, but not aztreonam, and may relate to unsuspected b-lactamases able to degrade BAL19764 but not aztreonam, or to variation in the expression of siderophore-related uptake pathways accessible to BAL19764 but not to aztreonam.
Results for Enterobacteriaceae mutants, transconjugants and transformants indicated that resistance to BAL19764 was conferred by AmpC enzymes, ESBLs and KPC carbapenemases, but not MBLs or OXA-48 carbapenemase. AmpC derepression had its greatest effect in Enterobacter and C. freundii, where Livermore et al.
expression of these enzymes can account for up to 3 -4% of cell protein; 19 resistance mediated by ESBLs varied with the enzyme type, being least with CTX-M b-lactamases (except CTX-M-15) but more marked with common SHV variants, notably SHV-5. BAL29880 overcame all resistance associated with AmpC enzymes in the laboratory mutants and clavulanate overcame all associated with ESBLs in the transconjugants and transformants, leaving BAL30376 consistently active.
BAL30376 had good, if less universal, activity against clinical isolates with these modes of resistance: MICs were ≤1 mg/L for 84% of ESBL producers and ≤4 mg/L for 94%; corresponding proportions for AmpC hyperproducers were 69% and 85%, respectively. More frequent resistance to BAL30376 was seen in porin-deficient AmpC or ESBL producers, 43% of which required MICs.4 mg/L. Superficially, this result might seem to imply that uptake of BAL19764 remains porin-dependent despite the compound's siderophore group, but plausibly might be because porin loss restricts entry of the clavulanate and BAL29880, preventing them from protecting BAL19764. Enterobacteriaceae with KPC carbapenemases were resistant to BAL30376, reflecting clavulanate's poor inhibitory activity against these enzymes. 20 Despite its activity against transformants with MBLs or OXA-48 enzyme, unprotected BAL19764 lacked activity against many clinical isolates with these enzymes, probably owing to co-production of AmpC or ESBL enzymes; this problem was substantially overcome by BAL30376, with its inclusion of inhibitors of AmpC and ESBL enzymes.
Derepression of AmpC caused resistance to unprotected BAL19764 in P. aeruginosa, as in Enterobacteriaceae and, again, this was reversed by BAL30376, proving that BAL29880 permeates the species and is not overwhelmingly effluxed. This is important, since AmpC derepression is the predominant mode of b-lactamase-associated resistance in P. aeruginosa. 21, 22 BAL30376 also-via the activity of clavulanate-overcame BAL19764 resistance mediated by PER-1 b-lactamase, a In summary, the strategy of combining an MBL-stable monobactam with inhibitors of AmpC enzymes and ESBLs is fundamentally sound. Nevertheless, the activity of BAL30376 against AmpC-hyperproducing and ESBL-producing Enterobacteriaceae was less consistent than for carbapenems, with scattered resistance among b-lactamase producers and non-producers, perhaps relating to variation in uptake. Strains with KPC carbapenemases were consistently resistant. Activity against P. aeruginosa was good, with AmpC-mediated resistance overcome, though not that mediated by efflux. Activity against major A. baumannii clones and B. cepacia was impressive, though less than for a related compound, the siderophore monosulfactam BAL30072. 28 
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